Peregrine flies higher on Phase III bavituximab plan
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals closed up 18.8% at $1.83 per share after the company said it reached an agreement with the US FDA on a Phase III clinical trial design for its beleaguered lead product candidate bavituximab.